Sitagliptin, metformin (Simedab, Jantaform)
Sitagliptin, metformin
Hetero Drugs South Africa (Pty) Ltd
Registration
- Applicant
- Hetero Drugs South Africa (Pty) Ltd
- Registrations
- 6
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Simedab 50/500 EACH TABLET CONTAINS: SITAGLIPTIN PHOSPHATE EQUIVALENT TO SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 500,0 mg | 50/500 | 59015459/21.2/0154 | Registered | Not determined | None |
| Simedab 50/850 EACH TABLET CONTAINS: SITAGLIPTIN PHOSPHATE EQUIVALENT TO SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 850,0 mg | 50/850 | 59015559/21.2/0155 | Registered | Not determined | None |
| Simedab 50/1 000 EACH TABLET CONTAINS: SITAGLIPTIN PHOSPHATE EQUIVALENT TO SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 1 000,0 mg | 50/1 000 | 590156 | Registered | Not determined | None |
| Jantaform 50/500 EACH TABLET CONTAINS: SITAGLIPTIN PHOSPHATE EQUIVALENT TO SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 500,0 mg | 50/500 | 590157.154 | Registered | Not determined | None |
| Jantaform 50/850 EACH TABLET CONTAINS: SITAGLIPTIN PHOSPHATE EQUIVALENT TO SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 850,0 mg | 50/850 | 590158.15559/21.2/0158.155 | Registered | Not determined | None |
| Jantaform 50/1 000 EACH TABLET CONTAINS: SITAGLIPTIN PHOSPHATE EQUIVALENT TO SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 1 000,0 mg | 50/1 000 | 590159.15659/21.2/0159.156 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.